Article information
Full text is only aviable in PDF
Bibliografía
[1.]
M.M. McNeil, S.L. Nash, R.A. Haijeh, R.A. Majjeh, M.A. Phelan, L.A. Conn, et al.
Trends in mortality due o invasive mycotic diseases in the United States 1980–1987.
Clin Infect Dis, 33 (2001), pp. 641-647
[2.]
L. Kaiser, T. Huguenin, P.O. Lew, R. Chapis, D. Pilter.
Invasive aspergillosis. Clinical features of 35 proven cases at a single institution.
Medicine (Baltimore), 77 (1998), pp. 188-194
[3.]
A.M. Groll, P.M. Shach, C. Mentzel, M. Schneider, Just, J. Nuebling, et al.
Trends in the post morten epidemiology of invasive fungal infections et a University hospital.
J Infect, 33 (1996), pp. 23-32
[4.]
O. Lortholary, S. Asloglus, P. Moreau, R. Herbrecht, A. Marimis, P. Casassus, et al.
Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma. A European Organization for Research and Treatment or Cancer Invasive Fungal Infections. Cooperative Group ant the Intergroupe Francais du Myeloma.
Clin Infect Dis, 30 (2000), pp. 41-46
[5.]
S.J. Lin, S. Schranz, S.M. Thentsch.
Aspergillosis case-fatality rate: systematic review of the literature.
Clin Infect Dis, 32 (2001), pp. 358-366
[6.]
K.A. Marr, R.A. Bowden.
Fungal infections in patients undergoing blood ant marrow transplantion.
Transpl Infect Dis, 1 (1999), pp. 237-246
[7.]
J.L. Vincent, D.J. Bihari.
The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIIC) Study.
Jama, 274 (1995), pp. 639-644
[8.]
F. Álvarez Lerma, R. Cerda E Jordá, M. Palomar, M. Bermejo.
Fungal isolates in critically patients admitted to intensive care units.
Intensive Care Med, 26 (2000), pp. 234
[9.]
M.A. Sánchez, C. León, J. Nolla, R. Jordá, M.A. León, M.J. Pontes.
and Study Group EPCAN. Use of antifungal agents in critically ill patients. A Spanish multicentre study. Final results.
Intensive Care Med, 26 (2000), pp. 376
[10.]
The genus Aspergillus,
[11.]
F.M. Van den Bergh, P.E. Verweij, A. Voss.
Epidemiology of nosocomial fungal infections: invasive aspegillosis.
Diagn Microbiol Infect Dis, 34 (1999), pp. 221-227
[12.]
A.O. Soubani, P.K. Chandrasekar.
The clinical spectrum of pulmonary aspergillosis.
Chest, 121 (2002), pp. 1988-1999
[13.]
P.E. Verweij, B.E. De Pauw.
Avances recientes en el manejo de la aspergilosis nosocomial en unidades onco-hematológicas.
Infección, pp. 157-176
[14.]
P. Ussetti, A. De Pablo, M. Cruz.
Aspergilosis pulmonar.
Implicaciones terapéuticas de la neumonía nosocomial grave, pp. 97-108
[15.]
C.J. Clancy, M.H. Ngujen.
acute communite-acquired pneumonia due to Aspergillus in presumably immunocompetens hosts.
Chest, 114 (1998), pp. 629-634
[16.]
H.J. Schwartz, P.A. Greenberger.
The prevalence of allergic bronchopulmonary aspergillosis in patients with asthma, determined by serologic and radiologic criteria in patients at risk.
J Lab Clin Med, 117 (1991), pp. 138-142
[17.]
G. Mastella, M. Rainisio, H.K. Harms, M.E. Hodson, C. Koch, J. Navarro, et al.
Allergic bronchopulmonary aspergillosis in cystic fibrosis. A Eurpean epidemiological study.
Eur Respir J, 16 (2000), pp. 464-471
[18.]
O.P. Sharma, R. Chwogule.
Many faces of pulmonary aspergillosis.
Eur Respir J, 12 (1998), pp. 705-715
[19.]
R. Patterson, P.A. Greenberger, R.C. Radin, M. Roberts.
Allergic bronchopulmonary aspergillosis: staging as an aid to management.
Ann Intern Med, 198 (1998), pp. 286-291
[20.]
P.A. Rosenberg, R. Patterson, R. Mintzer, et al.
Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis.
Ann Intern Med, 86 (1977), pp. 405-414
[21.]
P.A. Greenberger, R. Patterson.
Diagnosis and management of allergic bronchopulmonary aspergillosis.
Ann Allergy, 56 (1986), pp. 444-452
[22.]
P.A. Greenberger, T.P. Miller, M. Roberts, L.L. Smith.
Allergic Bronchopulmonary aspergillosis in patients with and without bronchiectasis.
Ann Allergy, 70 (1993), pp. 333-338
[23.]
Proceedings of the Cystic Fibrosis Foundation ABPA Consensus Conference; 2001, June 12-13; Bethesda, Md
[24.]
M. Rosenberg, R. Patterson, M. Roberts, J. Wang.
The assessment of inmunologic and changes occurring during corticosteroid therapy for allergy bronchopulmonary aspergillosis.
Am J Med, 64 (1978), pp. 599-605
[25.]
B.H. Safirstein, M.F. D'Souza, G. Simon, E.H.C. Tai, J. Pepys.
Fiveyear follow-up of allergic bronchopulmonary aspergillosis.
Am Rev Respir Dis, 108 (1973), pp. 450-459
[26.]
J. Wang, R. Patterson, M. Roberts.
The manegement of allergic bronchopulmonary aspergillosis.
Am Rev Respir Dis, 120 (1979), pp. 87-92
[27.]
W.G. Middleton, I.C. Paterson, I.W.B. Grant, A.C. Douglas.
Asthmatic pulmonary eosinophilia: a review of 65 cases.
Br J Dis Chest, 71 (1977), pp. 115-122
[28.]
British Thoracic Association.
Inhaled beclomethasone dipropionate in allergic bronchopulmonary aspergillosis: report to the Research Committee of the British Thoracic Association.
Br J Dis Chest, 73 (1979), pp. 349-356
[29.]
D.C. Carrie, C. Lueck, H.B. Milburn.
Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis.
Thorax, 45 (1990), pp. 447-450
[30.]
G.K. Crompton, L.I.R. Milne.
Treatment of bronchopulmonary aspergillosis with clotrimazole.
Br J Dis Chest, 67 (1973), pp. 301-307
[31.]
D.J. Shale, J.A. Faux, D.J. Lane.
Trial of ketoconazole in non-invasive pulmonary aspergillosis.
Thorax, 42 (1987), pp. 26-31
[32.]
D.A. Stevens, H.J. Schwartz, J.Y. Lee, B.L. Moskovitz, D.C. Jerome, A. Catanzano, et al.
A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis.
N Engl J Med, 342 (2000), pp. 756-762
[33.]
J. Myers.
Bronchocentric granulomatosis.
Disease or diagnosis? Chest, 96 (1989), pp. 3-4
[34.]
D.N. Denning, D.A. Stevens.
Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases.
Rev Infect Dis, 12 (1990), pp. 1147-1201
[35.]
M.A. Martínez López, J.M. Peña, J. Quiralte, M.C. Fernández, J.J. González, M. Patrón.
Bronchocentric granulomatosis associated with pure red cell aplasia and lymphadenopathy.
Thorax, 47 (1992), pp. 131-133
[36.]
F. Reichemberger, J.M. Habicht, A. Gratwohl, M. Tamm.
Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients.
Eur Respir J, 19 (2002), pp. 743-755
[37.]
T.F. Patterson, W.R. Kirkpatrick, M. White, J.W. Hiemenz, J.R. Wingard, B. Dupont, et al.
Invasive aspergillosis: disease spectrum, treatment practices, and outcomes: 13 Aspergillus Study Group.
Medicine (Baltimore), 79 (2000), pp. 250-260
[38.]
J. Rello, M.E. Esandi, D. Mariscal, M. Gallego, C. Domingo, J. Vallés.
Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: report of eight cases and review.
Clin Infect Dis, 26 (1998), pp. 1473-1475
[39.]
P.A. Bulpa, A.M. Dive, M.G. Garrino, M.A. Delos, M.R. González, P.A. Ewrard, et al.
Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care?.
Intensive Care Med, 27 (2001), pp. 59-67
[40.]
B. Mehrad, G. Paciocco, F.J. Martínez, T.C. Ojo, M.D. Iannettoni, I.I.I. Lynch JP.
Spectrum of Aspergillus infection in lung transplant recipients. Case series and review of the literature.
Chest, 119 (2001), pp. 169-175
[41.]
E. Mylonakis, T.F. Barlam, T. Flanigan, J.D. Rich.
Pulmonary aspergillosis and invasive disease in AIDS. Review of 342 cases.
Chest, 114 (1998), pp. 251-262
[42.]
J.R. Perfect, G.M. Cox, J.Y. Lee, C.A. Kauffman, L. De Repentigny, S.W. Chapman, et al.
The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis.
Clin Infect Dis, 33 (2001), pp. 1824-1833
[43.]
D.A. Stevens, V.L. Kan, M.A. Judson, V.A. Morrison, S. Dummer, D.W. Denning, et al.
Practice guidelines for diseases caused by Aspergillus. Infection Diseases Society of America.
Clin Infect Dis, 30 (2000), pp. 696-709
[44.]
M.J. Brown, S.A. Warthy, J.D. Flint.
Invasive aspergillosis in the inmunocompromised host: utility of computed tomography and bronchoalveolar lavage.
Clin Radiol, 53 (1998), pp. 255-257
[45.]
T. Franquet, N.L. Muller, A. Giménez, P. Guembe, J. De la Torre, S. Bague.
Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings.
Radiographics, 21 (2001), pp. 825-837
[46.]
M. Kami, T. Fukui, S. Ogawa.
Use of real-time pcr on blood samples for diagnosis of invasive aspergillosis.
Clin Infect Dis, 33 (2001), pp. 1504-1512
[47.]
J. Maertens, J. Verhaegen, K. Lagrou.
Screening for circulating galactomannan as a noninvasive diagnosis tool for invasive aspergillosis in prolonged neutropenic patient and stem cell trasplantation recipients: a prospective validation.
Blood, 97 (2001), pp. 1604-1610
[48.]
L. Turín, F. Riva, G. Galbiati, T. Cainelli.
Fast, simple and highly sensitive double-rounded polymerase chain reaction assay to detect medically relevant fungi in dermatological specimens.
Eur J Clin Invest, 30 (2000), pp. 511-518
[49.]
H. Herbart, J. Loffler, C. Meisner.
Early detection of Aspergillus infection after allogeneic stem cell transplantation by polimerasa chain reaction screening.
J Infect Dis, 181 (2000), pp. 1713-1719
[50.]
J. Loffler, H. Hebart, U. Brauchle, U. Schumacher, H. Einsele.
Comparison between plasma and whole blood specimens for detection of Aspergillus DNA by PCR.
J Clin Microbiol, 38 (2000), pp. 3830-3833
[51.]
T.J. Walsh, J.W. Hiemenz, N.L. Seibel, J.R. Perfect, G. Harwith, L. Lee, et al.
Amphotericin B lipid complex for invasive fungal infections: análisis of safety and efficacy in 556 cases.
Clin Infect Dis, 26 (1998), pp. 1383-1396
[52.]
J. Tollemar, L. Klingspor, O. Ringlen.
Liposomal amphotericin B (AmBisome) for fungal infection in immunocompromised aduts and children.
Clin Microbiol Infect, 7 (2001), pp. 68-79
[53.]
D.W. Denning, J.Y. Lee, J.S. hostetler, P. Pappas, C.A. Kauffman, D.H. Dewsnup, et al.
Mycosis Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis.
Am J Med, 97 (1994), pp. 135-144
[54.]
D.A. Stevens, J.Y. Lee.
Analysis of compassionate use itraconazole for invasive aspergillosis by the NIAID Mycosis Study Group creteria.
Arch Intern Med, 157 (1997), pp. 1857-1862
[55.]
D. Caillot, H. Bassaris, A. McGeer, C. Arthur, H.G. Prentice, W. Seifert, et al.
Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chornic granulomatous disease, o AIDS.
Clin Infect Dis, 33 (2001), pp. E83-E90
[56.]
C.A. Thompson.
New type of antifungal approved for invasive aspergillosis.
Am J Health Syst Pharm, 58 (2001), pp. 558
[57.]
R. Herbrecht, D.W. Denning, T.F. Patterson, J.E. Bennett, R.E. Greene, J.U.V. Oestmann, et al.
Open randomized of voriconazole and amphotericin B followed by other licensed antifungal therapy for primary therapy of invasive aspergillosis.
American Society for Microbiology, pp. 378
[58.]
R. Herbrecht, D.W. Denning, F.T. Patterson, E. Bennet, for the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group.
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
N Engl J Med, 347 (2002), pp. 408-415
[59.]
C.H. Pun, J.M. Boyett, W.T. Hughes, W.M. Crist.
A randomized, placebo- controlled trial of recombinant human granulocyte colony-stimulating factor after remission induction chemotherapy in children with acute lymphocytic leukemia.
N Engl J Med, 336 (1997), pp. 1781-1787
[60.]
J. Numonaitis.
Use of macrophage colony-atimulating factor in the treatment of fungal infections.
Clin Infect Dis, 26 (1998), pp. 1279-1281
[61.]
J.M. Rowe.
Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections.
Clin Infect Dis, 26 (1998), pp. 1290-1294
[62.]
Y. Kanda, R. Yamamoto, A. Chizuka, T. Hamaki, H. Suguro, C. Arai, et al.
Prophylactic action of oral fluconazole agains fungal infection en neutropenic patients. A meta-analysis of 16 randomized, controlled trials.
Cancer, 89 (2000), pp. 1611-1625
[63.]
S. Schwartz, G. Behre, V. Heinemann, K. Lenz, W.D. Ludwig, H. Wandt, et al.
Aerosolized amphotericin B inhalations as prophylasis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial.
Blood, 93 (1999), pp. 3654-3661
[64.]
N. Singh.
Antifungal prophylaxis for solid sorgan transplant recipients: seeking clarity amidst controversy.
Clin Infect Dis, 31 (2000), pp. 545-553
[65.]
J.E. Patterson, J. Peters, J.H. Calhoon, S. Levine, A. Anzueto, H. Al-Abdely, et al.
Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients.
Transpl Infect Dis, 2 (2000), pp. 22-28
[66.]
R.P. Baughman.
The lung in the inmunocompromised patient. Infectious complications part 1.
Respiration, 66 (1999), pp. 95-100
[67.]
A. De Pablo, P. Ussetti, M.C. Carreño, T. Lázaro, M.J. Ferreiro, A. López, et al.
Aspergilosis en el trasplante pulmonar.
Enferm Infecc Microbiol Clin, 18 (2000), pp. 209-214
[68.]
T. Birsan, S. Taghavi, W. Klepetko.
Treatment of aspergillus-related ulcerative tracheobronchitis in lung transplant recipients.
J Heart Lung Transplant, 17 (1998), pp. 437-438
[69.]
J. Hamacher, A. Apilioponlos, A.M. Kurt.
Pre-emptive therapy with azoles in lung transplant patients.
Eur Respir J, 13 (1999), pp. 180-186
[70.]
T. Kato, U. Ikuji, M. Hiroki, G. Mashiro, H. Masayoshi, N. Atsushi, et al.
Chonic necrotizing pulmonary aspergillosis in pneumoconiosis. Clinical and radiologic findings in 10 patients.
Chest, 121 (2002), pp. 118-127
[71.]
T. Franquet, N.L. Muller, A. Giménez, P. Domingo, V. Plaza, R. Bordes.
Semiinvasive pulmonary aspergillosis in chronic obstructive pulmonary disease: radiologic and pathologic findings in nine patients.
AJR Am J Roentgenol, 174 (2000), pp. 51-56
[72.]
D.W. Denning.
Chronic forms of pulmonary aspergillosis.
Clin Microbiol Infect, 7 (2001), pp. 25-31
[73.]
M.W. Pound, R.H. Drew, J.R. Perfect.
Recent andvances in the epidemiology prevention, diagnosis, and treatment of fungal pneumonia.
Curr Opin Infect Dis, 15 (2002), pp. 183-194
[74.]
S. Kawamura, S. Maesaki, K. Tomono, T. Tashiro, S. Kohno.
Clinical evaluation of 61 patient with pulmonary aspergilloma.
Intern Med, 39 (2000), pp. 209-212
[75.]
British Tuberculosis and Thoracic Association.
Aspergilloma and residual tuberculous cavities: the results of a resurvey.
Tubercle, 41 (1970), pp. 227-245
[76.]
H. Yamada, S. Kono, H. Koga.
Topical treatment of pulmonary aspergilloma and antifungals: relationship between duration of the disease and efficacy of therapy.
Chest, 103 (1993), pp. 1421-1425
[77.]
P.L. Munk, A.D. Vellet, R.N. Rankin, N.L. Muller, D. Ahmad.
Intracavitary aspergilloma: transthoracic percutaneous injection of amphotericin gelatin solution.
Radiology, 188 (1993), pp. 821-823
[78.]
M. Rumbak, G. Kohler, C. Eastrige, H. Winer-Muram, M. Gravant.
Topical treatment of life-threatening hemoptysis fom aspergilloma.
Thorax, 51 (1996), pp. 253-255
[79.]
G. Massard, N. Roeslin, J.M. Wihlm, P. Dumont, J.P. Witz, G. Morand.
Pleuropulmonary aspergyloma: clinical spectrum and result of surgical treatment.
Ann Thorax Surg, 54 (1992), pp. 1159-1164
[80.]
J.F. Regnard, P. Icard, M. Nicolosi.
Aspergilloma: a series of 89 surgical cases.
Ann Thorac Sug, 69 (2000), pp. 898-903
Copyright © 2004. Sociedad Española de Neumología y Cirugía Torácica
